scholarly journals Copper isotope for potential thyroid cancer diagnosis

2021 ◽  
Author(s):  
Latifa Sarra Kazi Tani ◽  
Alexandra Gourlan ◽  
Nouria Dennouni-Medjati ◽  
Majda Dali Sahi ◽  
Yahia Harek ◽  
...  
Author(s):  
Yi‐Cheng Zhu ◽  
Hongbo Du ◽  
Quan Jiang ◽  
Tao Zhang ◽  
Xu‐Juan Huang ◽  
...  

2017 ◽  
Vol 11 (1) ◽  
pp. 6-27 ◽  
Author(s):  
Dmitriy G. Beltsevich ◽  
Vladimir E. Vanushko ◽  
Pavel O. Rumiantsev ◽  
Galina A. Melnichenko ◽  
Nikolay S. Kuznetsov ◽  
...  

В представленных клинических рекомендациях обсуждаются современные подходы к диагностике и лечению дифференцированного рака щитовидной железы у взрослых. Изменения в настоящей редакции Клинических рекомендаций касаются показаний к пункционной биопсии, скринингового определения концентрации кальцитонина, унификации заключений цитологического исследования, новых подходах к послеоперационной динамической стратификации риска рецидива, показаний к супрессивной и заместительной терапии, таргетной терапии йоднегативных форм дифференцированного рака щитовидной железы.


2021 ◽  
Author(s):  
Iuri Martin Goemann ◽  
Francisco Paixão ◽  
Alceu Migliavaca ◽  
José Ricardo Guimarães ◽  
Rafael Selbach Scheffel ◽  
...  

Abstract Purpose: A primary medical relevance of thyroid nodules consists of excluding thyroid cancer, present in approximately 5% of all thyroid nodules. Fine-needle aspiration biopsy (FNAB) has a paramount role in distinguishing benign from malignant thyroid nodules due to its availability and diagnostic performance. Nevertheless, intraoperative frozen section (iFS) is still advocated as a valuable tool for surgery planning, especially for indeterminate nodules. Methods: To compare the FNAB and iFS performances in thyroid cancer diagnosis among nodules in Bethesda Categories (BC) I to VI. The performance of FNAB and iFS tests were calculated using final histopathology results as the gold standard.Results: In total, 316 patients were included in the analysis. Both FNAB and iFS data were available for 272 patients (86.1%). The overall malignancy rate was 30.4%% (n=96). The FNAB sensitivity, specificity, and accuracy for benign (BC II) and malignant (BC V and VI) were 89.5%, 97.1%, and 94.1%, respectively. For all nodules evaluated, the iFS sensitivity, specificity, and accuracy were 80.9%, 100%, and 94.9%, respectively. For indeterminate nodules and follicular lesions (BC III and IV), the iFS sensitivity, specificity, and accuracy were 25%, 100%, and 88.7%, respectively. For BC I nodules, iFS had 95.2% of accuracy.Conclusion: Our results do not support routine iFS for indeterminate nodules or follicular neoplasms (BC III and IV) due to its low sensitivity. In these categories, iFS is not sufficiently accurate to guide the intraoperative management of thyroidectomies. iFS for BC I nodules could be a reasonable option and should be specifically investigated.


Author(s):  
Archana Radhakrishnan ◽  
David Reyes-Gastelum ◽  
Paul Abrahamse ◽  
Brittany Gay ◽  
Sarah T Hawley ◽  
...  

Abstract Context Little is known about provider specialties involved in thyroid cancer diagnosis and management. Objective Characterize providers involved in diagnosing and treating thyroid cancer. Design/Setting/Participants We surveyed patients with differentiated thyroid cancer from the Georgia and Los Angeles County SEER registries (N=2632, 63% response rate). Patients identified their primary care physicians (PCP), who were also surveyed (N=162, 56% response rate). Main outcome measures 1) patient-reported provider involvement (endocrinologist, surgeon, PCP) at diagnosis and treatment; 2) PCP-reported involvement (more vs. less) and comfort (more vs. less) with discussing diagnosis and treatment. Results Among thyroid cancer patients, 40.6% reported being informed of their diagnosis by their surgeon, 37.9% by their endocrinologist, and 13.5% by their PCP. Patients reported discussing their treatment with their surgeon (71.7%), endocrinologist (69.6%), and PCP (33.3%). Physician specialty involvement in diagnosis and treatment varied by patient race/ethnicity and age. For example, Hispanic patients (vs. non-Hispanic White) were more likely to report their PCP informed them of their diagnosis (OR: 1.68, 95%CI: 1.24-2.27). Patients ≥65years (vs. <45years) were more likely to discuss treatment with their PCP (OR: 1.59; 95%CI 1.22-2.08). Although 74% of PCPs reported discussing their patients’ diagnosis and 62% their treatment, only 66% and 48% respectively were comfortable doing so. Conclusions PCPs were involved in thyroid cancer diagnosis and treatment and their involvement was greater among older patients and patients of minority race/ethnicity . This suggests an opportunity to leverage PCP involvement in thyroid cancer management to improve health and quality of care outcomes for vulnerable patients.


Sign in / Sign up

Export Citation Format

Share Document